Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 128.34 as of 2026-10-06T14:21:00.708Z.
Consensus retrieved: 2026-10-06T09:30:54.955Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:21:00.708Z.
Quote observation: 2026-10-06T14:20:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 38b5431cb1e3da682f5ebe5fe36c67887aeb28768e172b1d79306996b6f580d0
Forward PE Ratio (128.34) = Dated Quote Price ($101.94) / Consensus Forward EPS ($0.79)
FORWARD PE RATIO
128.34
SECTOR MEDIAN · HEALTHCARE
19.56
median of 152 covered companies
CURRENT VS SECTOR MEDIAN
+555.97%
vs the sector median at left
BillionToOne, Inc.
Market Cap
$4.69B
Forward PE Ratio
128.34
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BillionToOne, Inc. (BLLN) | $4.69B | 128.34 |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.70B | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.64B | 74.47 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.63B | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.81B | N/A |
| Erasca, Inc. (ERAS)vs › | $4.88B | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.43B | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.39B | 8.33 |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.37B | N/A |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.03B | N/A |
Trailing P/E
164.4
reported TTM EPS
Forward P/E
128.3
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.79 implies +27.4% EPS growth vs the reported trailing $0.62.
At the dated quote price of $101.94, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.79 | $0.73 – $0.91 | 4 | 128.3x |
| 2027-12-31 | $1.02 | $0.76 – $1.37 | 4 | 99.5x |
| 2028-12-31 | $1.77 | $1.19 – $2.52 | 6 | 57.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
